JP2002201141A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002201141A5 JP2002201141A5 JP2001116710A JP2001116710A JP2002201141A5 JP 2002201141 A5 JP2002201141 A5 JP 2002201141A5 JP 2001116710 A JP2001116710 A JP 2001116710A JP 2001116710 A JP2001116710 A JP 2001116710A JP 2002201141 A5 JP2002201141 A5 JP 2002201141A5
- Authority
- JP
- Japan
- Prior art keywords
- ifn
- activity
- sample
- cells
- determined
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2001116710A JP2002201141A (ja) | 2000-10-27 | 2001-04-16 | 蛋白質合成抑制遺伝子の発現増強剤 |
| CA002395324A CA2395324A1 (en) | 2000-10-27 | 2001-09-26 | Expression potentiator for protein synthesis regulatory gene |
| EP01972507A EP1329223A4 (en) | 2000-10-27 | 2001-09-26 | EXPRESSION AMPLIFIER FOR PROTEIN SYNTHESIS OF REGULATORY GENES |
| KR1020027008401A KR100830268B1 (ko) | 2000-10-27 | 2001-09-26 | 단백질 합성 억제 유전자의 발현 증강제 |
| US09/962,625 US6773701B2 (en) | 2000-10-27 | 2001-09-26 | Expression enhancer for protein synthesis inhibitory genes |
| PCT/JP2001/008390 WO2002036153A1 (en) | 2000-10-27 | 2001-09-26 | Expression potentiator for protein synthesis regulatory gene |
| TW090125438A TWI283582B (en) | 2000-10-27 | 2001-10-15 | Expression potentiator for protein synthesis regulatory gene |
| US10/777,081 US7189389B2 (en) | 2000-10-27 | 2004-02-13 | Pharmaceutical composition of human interferon-α2 and interferon α8 subtypes |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2000-328539 | 2000-10-27 | ||
| JP2000328539 | 2000-10-27 | ||
| JP2001116710A JP2002201141A (ja) | 2000-10-27 | 2001-04-16 | 蛋白質合成抑制遺伝子の発現増強剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002201141A JP2002201141A (ja) | 2002-07-16 |
| JP2002201141A5 true JP2002201141A5 (cg-RX-API-DMAC7.html) | 2008-05-15 |
Family
ID=26602905
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001116710A Pending JP2002201141A (ja) | 2000-10-27 | 2001-04-16 | 蛋白質合成抑制遺伝子の発現増強剤 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US6773701B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1329223A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2002201141A (cg-RX-API-DMAC7.html) |
| KR (1) | KR100830268B1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2395324A1 (cg-RX-API-DMAC7.html) |
| TW (1) | TWI283582B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2002036153A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9453251B2 (en) | 2002-10-08 | 2016-09-27 | Pfenex Inc. | Expression of mammalian proteins in Pseudomonas fluorescens |
| JP4629964B2 (ja) * | 2003-09-12 | 2011-02-09 | 株式会社林原生物化学研究所 | ウシの消化器疾患治療剤 |
| CN101031655A (zh) | 2004-07-26 | 2007-09-05 | 陶氏环球技术公司 | 通过株工程改进蛋白表达的方法 |
| EP1867340A4 (en) | 2005-03-10 | 2009-12-23 | Hayashibara Biochem Lab | THERAPEUTIC AGENT FOR TREATING DISEASES IN THE BOVINE DIGESTIVE SYSTEM |
| JPWO2007037098A1 (ja) * | 2005-09-27 | 2009-04-02 | 株式会社林原生物化学研究所 | 繁殖障害改善剤 |
| US9580719B2 (en) | 2007-04-27 | 2017-02-28 | Pfenex, Inc. | Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins |
| US9394571B2 (en) | 2007-04-27 | 2016-07-19 | Pfenex Inc. | Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins |
| CN104056254A (zh) * | 2013-03-18 | 2014-09-24 | 赛德医药科技股份有限公司 | 用以降低肝炎病患复发率的组合物 |
| US10077420B2 (en) | 2014-12-02 | 2018-09-18 | Histogenics Corporation | Cell and tissue culture container |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5142199B2 (cg-RX-API-DMAC7.html) | 1972-09-04 | 1976-11-13 | ||
| GB2016015B (en) | 1978-01-22 | 1982-05-06 | Hayashibara Co | Method of preparing interferon and preparations containing interferon |
| JPS5639022A (en) | 1979-09-05 | 1981-04-14 | Hayashibara Biochem Lab Inc | Preparation of vaccine |
| JPS5654158A (en) | 1979-10-09 | 1981-05-14 | Hitachi Ltd | Control system for call waiting |
| JP2838800B2 (ja) | 1989-09-02 | 1998-12-16 | 株式会社林原生物化学研究所 | 減感作剤 |
| US5503828A (en) * | 1992-02-10 | 1996-04-02 | Interferon Sciences, Inc. | Alpha interferon composition and method for its production from human peripheral blood leukocytes |
| JP3232488B2 (ja) | 1992-08-20 | 2001-11-26 | 株式会社林原生物化学研究所 | プルラン高含有物とその製造方法並びに用途 |
| US5780021A (en) * | 1993-03-05 | 1998-07-14 | Georgetown University | Method for treating type 1 diabetes using α-interferon and/or β-i |
| JPH07163368A (ja) | 1993-12-15 | 1995-06-27 | Hayashibara Biochem Lab Inc | 組換えdnaとその組換えdnaを含む形質転換体 |
| EP0785276A4 (en) | 1994-09-29 | 2002-01-09 | Ajinomoto Kk | MODIFICATION OF A PEPTIDE AND A PROTEIN |
| JP3467515B2 (ja) * | 1994-11-01 | 2003-11-17 | 財団法人ルイ・パストゥール医学研究センター | インターフェロン活性の測定法 |
| MY125300A (en) * | 1999-02-26 | 2006-07-31 | Inst Of Molecular And Cell Biology | Synergistic combination for treatment of viral-mediated diseases |
-
2001
- 2001-04-16 JP JP2001116710A patent/JP2002201141A/ja active Pending
- 2001-09-26 US US09/962,625 patent/US6773701B2/en not_active Expired - Fee Related
- 2001-09-26 CA CA002395324A patent/CA2395324A1/en not_active Abandoned
- 2001-09-26 KR KR1020027008401A patent/KR100830268B1/ko not_active Expired - Fee Related
- 2001-09-26 EP EP01972507A patent/EP1329223A4/en not_active Ceased
- 2001-09-26 WO PCT/JP2001/008390 patent/WO2002036153A1/ja not_active Ceased
- 2001-10-15 TW TW090125438A patent/TWI283582B/zh not_active IP Right Cessation
-
2004
- 2004-02-13 US US10/777,081 patent/US7189389B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lonberg-Holm et al. | Unrelated animal viruses share receptors | |
| Fife et al. | Valaciclovir versus acyclovir in the treatment of first-episode genital herpes infection: results of an international, multicenter, double-blind, randomized clinical trial | |
| Amano et al. | Salivary receptors for recombinant fimbrillin of Porphyromonas gingivalis | |
| DE60119734D1 (de) | Hpv-e7 zur behandlung von menschlichem papillomavirus | |
| JP2002513768A5 (cg-RX-API-DMAC7.html) | ||
| Lucht et al. | Entamoeba gingivalis in human immunodeficiency virus type 1-infected patients with periodontal disease | |
| UA66744C2 (en) | 5,6-dichlorobenzimidazole derivatives, methods for the preparation thereof, pharmaceutical composition and method for treatment of viral infections | |
| Jones et al. | Between‐subject and within‐subject variations in the pharmacokinetics of ethanol. | |
| JP2006511450A (ja) | 治療用ウイルスの投与 | |
| AR035867A1 (es) | Una particula semejante a un virus hcv formada por una proteina de envoltura de hcv, un metodo para formar dicha particula, un medicamento que la contiene, una vacuna, un metodo de deteccion, un kit de diagnostico, el uso de cepas de hansenula o saccharomyces para la expresion de una proteina hcv, e | |
| Wolcott et al. | Exposure to ozone reduces influenza disease severity and alters distribution of influenza viral antigens in murine lungs | |
| Favié et al. | Pharmacokinetics of favipiravir during continuous venovenous haemofiltration in a critically ill patient with influenza | |
| Barteling | A simple method for the preparation of agarose | |
| Rezkalla et al. | Effect of indomethacin in the late phase of coxsackievirus myocarditis in a murine model | |
| Martin et al. | Comparative bioavailability of two furosemide formulations in humans | |
| US20100267616A1 (en) | Acute respiratory syndromes | |
| Ruzicka et al. | A probable case of rotavirus exanthem | |
| Gall | Human papillomavirus infection and therapy with interferon | |
| Youngner et al. | Interferon production in mice by vesicular stomatitis virus | |
| Weiner et al. | Viral hemorrhagic fevers-a recurrent public health threat | |
| Khanna et al. | Regulation of vascular permeability by macrophage‐derived chemotactic factor produced in Japanese encephalitis | |
| McLean et al. | Infections with enteroviruses in Toronto, 1961 | |
| Giusti et al. | Etiological, clinical and laboratory data of post-transfusion hepatitis: a retrospective study of 379 cases from 53 Italian hospitals | |
| Pereira | Occurrence of adenovirus type 21 in Great Britain | |
| Flamenbaum | Propranolol versus labetalol: interesting differences in efficacy |